SPRO - Spero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.21
-0.14 (-1.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.35
Open12.33
Bid0.00 x 1200
Ask0.00 x 2900
Day's Range12.03 - 12.33
52 Week Range5.52 - 18.23
Volume27,490
Avg. Volume80,059
Market Cap210.207M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.60
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • The travel industry is extremely resilient, says Expedia CEO
    CNBC Videos3 months ago

    The travel industry is extremely resilient, says Expedia CEO

    Expedia President and CEO Mark Okerstrom joins "Squawk on the Street" to discuss the company's strong earnings and what the state of travel is for the United States and around the world.

  • GlobeNewswire18 days ago

    Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases

    CAMBRIDGE, Mass., April 08, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • Spero Gets Fast Track Designation for SPR994, Shares Improve
    Zacks24 days ago

    Spero Gets Fast Track Designation for SPR994, Shares Improve

    Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.

  • GlobeNewswire28 days ago

    Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis

    CAMBRIDGE, Mass., March 29, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • GlobeNewswirelast month

    Spero Announces Appointment of Cynthia Smith to its Board of Directors

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced the appointment of Cynthia Smith to its Board of Directors, effective as of today. “We are pleased to welcome Cynthia to our Board of Directors,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.

  • Will Spero Therapeutics Continue to Surge Higher?
    Zackslast month

    Will Spero Therapeutics Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Spero Therapeutics.

  • Business Wirelast month

    Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review

    Anticipated 2019 Events include Enrollment in the Planned SPR994 Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206 Phase 1 Clinical Trials in 2H19

  • Associated Presslast month

    Airbnb, HomeAway lose legal challenge to Santa Monica rules

    Short-term rental sites Airbnb and HomeAway lost a legal challenge Wednesday against an ordinance enacted by a popular California tourist city. The ordinance imposed several obligations involving rental sites in seaside Santa Monica, including refraining from booking properties that are not licensed and listed on a city registry. A 9th U.S. Circuit Court of Appeals panel ruled that a lower court properly dismissed the legal challenge over its failure to state a claim against the city.

  • Airbnb Loses Major Fight Over California City's Rental Law
    Bloomberglast month

    Airbnb Loses Major Fight Over California City's Rental Law

    The ruling Wednesday by a three-judge panel of the Ninth Circuit is a setback for the home-sharing platforms in their effort to avoid regulation by cities that blame the rapid proliferation of short-term rentals for a shortage of affordable housing and a disintegration of residential communities. The Santa Monica ordinance holds the companies responsible for booking rentals of residences that aren’t licensed by the city. San Francisco-based Airbnb is the largest home-rental platform with more than 6 million listings around the world.

  • GlobeNewswire2 months ago

    Spero Therapeutics to Present at March Investor Conferences

    Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections. Spero’s lead product candidate, SPR994, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.  Spero has begun start-up activities for the ADAPT-PO Phase 3 clinical trial of SPR994 for the treatment of complicated urinary tract infections and anticipates opening trial sites to support study enrollment in the first quarter of 2019. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of non-tuberculous mycobacterial (NTM) infections.  In January 2019, Spero initiated a Phase 1 clinical trial of SPR720 in healthy subjects and expects top-line data from this trial in the second half of 2019.

  • GlobeNewswire2 months ago

    Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720

    CAMBRIDGE, Mass., Feb. 26, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • Are Spero Therapeutics, Inc.’s (NASDAQ:SPRO) Interest Costs Too High?
    Simply Wall St.2 months ago

    Are Spero Therapeutics, Inc.’s (NASDAQ:SPRO) Interest Costs Too High?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Spero Therapeutics, Inc. (NASDAQ:SPRO), which has zero-debt on its balanceRead More...

  • Expedia Analysts Grow More Bullish After Strong Earnings
    Bloomberg3 months ago

    Expedia Analysts Grow More Bullish After Strong Earnings

    While growth in Expedia’s home rental service disappointed, the company made up for it with strength in its core platform. Cowen also sees positive read-through to peers Booking Holdings Inc. and TripAdvisor Inc., which report later this month. “HomeAway was the major disappointment” in the fourth quarter and the lack of prior warning from management suggested it must have started to deteriorate at the end of the year, after third-quarter results.

  • Expedia Group Inc. (EXPE) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Expedia Group Inc. (EXPE) Q4 2018 Earnings Conference Call Transcript

    EXPE earnings call for the period ending December 31, 2018.

  • Expedia Shares Jump After 2019 Earnings Forecast Beats Estimates
    Bloomberg3 months ago

    Expedia Shares Jump After 2019 Earnings Forecast Beats Estimates

    Adjusted earnings before interest, tax, depreciation and amortization, will grow 10 percent to 15 percent in 2019, Chief Financial Officer Alan Pickerill said on a conference call Thursday. Analysts were projecting an increase of 9 percent, according to data compiled by Bloomberg. Analysts were looking for signs that Expedia’s performance would justify a runaway share price so far this year.

  • GlobeNewswire3 months ago

    Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994

    “With the FDA’s acceptance of our IND application for SPR994, we are excited to continue our Phase 3 initiation efforts, including opening clinical trial sites for enrollment in the U.S.," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.

  • GlobeNewswire3 months ago

    Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial

    “SPR720 is a promising drug candidate that has the potential to become the first approved oral treatment for NTM infections. NTM infections cause chronic, debilitating disease and represent an area of high unmet need as there are no specifically approved orally administered treatment options,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics. The Phase 1 clinical trial evaluating SPR720 is a double-blind, placebo-controlled, ascending dose, multi-cohort study in healthy subjects consisting of single ascending dose and multiple ascending dose cohorts.

  • Benzinga4 months ago

    The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...

  • GlobeNewswire4 months ago

    Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial

    SPR206 and SPR741, two intravenous (IV)-administered product candidates from Spero’s Potentiator Platform, are being developed as innovative options to treat MDR Gram-negative bacterial infections.  Based on microbiological and in vivo testing, Spero believes that SPR206 has the potential to offer a broad-spectrum of activity, including against extensively drug-resistant (XDR) bacterial strains, together with improved safety and tolerability compared with other molecules in its class. Spero initiated a Phase 1 clinical trial of SPR206 in December 2018, designed as a double-blind, placebo-controlled, ascending dose, multi-cohort study in healthy subjects, and expects top-line data from this trial in the second half of 2019.  Data from investigational new drug (IND)-enabling studies, together with data presented at the ESCMID/ASM Conference in September 2018, collectively demonstrate SPR206’s favorable safety profile and in vitro activity against MDR Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa.

  • GlobeNewswire4 months ago

    Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced the results of its Type B / pre-IND / pre-Phase 3 meeting with the U.S. Food and Drug Administration (FDA) regarding SPR994 for the oral treatment of complicated urinary tract infections (cUTI). Based on its discussions with the FDA, Spero believes that positive results from a single pivotal Phase 3 clinical trial of SPR994 in cUTI demonstrating a 10% non-inferiority margin would support the approval of SPR994 for the treatment of cUTI.

  • DAFNA Capital Management Return, AUM and Holdings
    Insider Monkey4 months ago

    DAFNA Capital Management Return, AUM and Holdings

    DAFNA Capital Management, LLC is a Los Angeles-based hedge fund launched by Dr. Nathan Fischel, back in 1999. Dr. Fischel is an experienced Pediatric Hematologist-Oncologist, who graduated from the Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. For his post-graduate studies […]

  • GlobeNewswire5 months ago

    New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss
    Zacks6 months ago

    Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss

    Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 6.25% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire6 months ago

    Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview

    Pipeline rapidly advancing with three clinical trials planned to initiate by early 2019, including a SPR994 Phase 3 initiation around year-end 2018 CAMBRIDGE, Mass., Nov. 08,.